In January 2026, the healthcare sector has seen significant short selling, particularly in biotechnology and healthcare services. Hims & Hers (HIMS) leads with a 32.95% short interest, followed by CRISPR Therapeutics (CRSP) at 22.81%. Conversely, BrightSpring Health Services (BTSGU) and Regencell Bioscience (RGC) have low short interests of 0.10% and 0.19%, respectively. The Health Care Select Sector SPDR Fund (XLV) has gained 0.78% this year, outperforming the S&P 500's 0.19% decline, indicating a shift in investor preference towards healthcare stocks.